前十大流通股东累计持有： 6373.06万股，累计占流通股比： 44.97%，较上期变化： -66.00万 股。 一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.0551 | 0.0643 | -14.31 | 0.2349 | | 每股净资产（元） | 10.06 | 10.51 | -4.28 | 13.99 | | 每股公积金(元) | 4.87 | 4.87 | 0 | 7.74 | | 每股未分配利润(元) | 3.87 | 4.17 | -7.19 | 4.75 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 0.24 | 0.34 | -29.41 | 1.45 | | 净利润(亿元) | 0.33 | 0.39 | -15.38 | 0.94 | | 净资产收益率(%) | 0.54 | 0.61 | -11.48 | 1.70 | 数据四舍五入，查看更多财务数据> ...

Financial Performance - The company's revenue for Q1 2025 was ¥24,282,534.72, representing a decrease of 29.05% compared to ¥34,222,695.90 in the same period last year[5] - Net profit attributable to shareholders was ¥32,777,072.14, down 15.06% from ¥38,589,463.38 year-on-year[5] - Total operating revenue decreased to ¥24,282,534.72 from ¥34,222,695.90, representing a decline of approximately 29.1% year-over-year[17] - Net profit for the period was ¥32,777,072.14, down from ¥38,589,463.38, reflecting a decrease of approximately 15.1% year-over-year[18] - Basic earnings per share decreased by 14.31% to ¥0.0551 from ¥0.0643 in the same period last year[5] - Basic earnings per share decreased to ¥0.0551 from ¥0.0643, a decline of about 14.3% year-over-year[19] - Other income decreased to ¥2,558,547.64 from ¥3,545,030.98, a decline of about 27.9% year-over-year[18] Cash Flow - The net cash flow from operating activities was negative at -¥2,587,625.81, a decline of 102.68% compared to ¥96,429,081.13 in the previous year[5] - Cash inflow from operating activities totaled $224.24 million, a decrease from $494.88 million year-over-year[22] - Cash outflow related to operating activities was $226.83 million, compared to $398.45 million in the previous period[22] - Cash received from sales of goods and services was ¥214,904,356.36, down from ¥487,216,616.88, a decline of about 55.8% year-over-year[21] - Cash flow from financing activities showed a net outflow of -$30.66 million, compared to -$1.52 million in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,443,158,707.85, a decrease of 1.06% from ¥7,523,255,843.58 at the end of the previous year[5] - The company's cash and cash equivalents decreased to CNY 490,186,996.72 from CNY 623,035,019.91, reflecting a decline of approximately 21.3%[14] - Accounts receivable decreased to CNY 1,276,094,419.94 from CNY 1,437,459,795.12, indicating a reduction of about 11.2%[14] - The company’s long-term assets decreased to CNY 2,384,676,612.06 from CNY 2,546,736,316.68, a decline of approximately 6.4%[15] - Total liabilities decreased to ¥1,395,440,931.16 from ¥1,510,111,321.68, a reduction of approximately 7.6% year-over-year[16] - Total equity increased to ¥6,047,717,776.69 from ¥6,013,144,521.90, reflecting a growth of about 0.6% year-over-year[16] Expenses - Management expenses decreased by 37.18% to ¥7,947,905.52, mainly due to reduced equity incentive costs and employee benefits[8] - Research and development expenses increased to ¥22,115,565.91 from ¥19,022,504.10, an increase of approximately 16.4% year-over-year[18] - The company reported a 100.92% increase in financial expenses to ¥32,632.44, attributed to a decrease in interest income[8] Shareholder Information - The company has a total of 6,027,467 shares held in a repurchase account, accounting for 1.00% of total shares, ranking it as the 5th largest shareholder[12] - The company has a significant shareholder, CYBER CREATOR LIMITED, holding 8.98% of shares, indicating a strategic partnership[12] Government Support - The company received government subsidies amounting to ¥2,558,543.66, which are closely related to its normal business operations[6] Other Financial Metrics - The weighted average return on net assets was 0.54%, down from 0.61% in the previous year[5] - Deferred income tax liabilities decreased to ¥17,126,331.11 from ¥18,800,579.72, a reduction of approximately 8.9% year-over-year[16] - The impact of exchange rate changes on cash and cash equivalents was $55,928, contrasting with a negative impact of -$45,054 in the previous period[22]

证券代码：301207 证券简称：华兰疫苗 公告编号：2025-024 华兰生物疫苗股份有限公司 2024年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东大会未出现否决议案的情形。 2.本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、本次股东大会的召开时间： 现场会议召开时间为：2025 年 4 月 25 日下午 13:00 网络投票时间：2025 年 4 月 25 日。其中通过深圳证券交易所交易系统进行网 络投票的具体时间为 2025 年 4 月 25 日上午 9:15—9:25,9:30—11:30 和下午 13:00— 15:00；通过深圳证券交易所互联网投票的具体时间为 2025 年 4 月 25 日 9:15 至 15:00 期间的任意时间。 2、会议召开地点：华兰生物疫苗股份有限公司（以下简称"公司"）办公楼会议 室 3、召集人：公司董事会 4、会议方式：现场投票、网络投票相结合的方式 5、现场会议主持人：董事长安康先生 6、本次股东大会的会议召集、召开程序符合有关法律、法 ...

关于 华兰生物疫苗股份有限公司 安徽承义律师事务所 召开 2024 年度股东大会的 法律意见书 安徽承义律师事务所 中国.合肥市政务区怀宁路 200 号栢悦中心 5 楼 邮编: 230022 电话（Tel）: （86-551）65609815 传真（Fax）: （86-551）65608051 网址（Website）: www.chengyi-law.com 电子信箱（E-mail）：chengyilawyer@163.com 安徽承义律师事务所 关于华兰生物疫苗股份有限公司 召开 2024 年度股东大会的法律意见书 （2025）承义法字第 00070 号 致：华兰生物疫苗股份有限公司 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股东 会规则》等法律法规和其他规范性文件的要求，安徽承义律师事务所接受华兰生 物疫苗股份有限公司（以下简称"公司"）的委托，指派束晓俊、万晓宇律师（以 下简称"本律师"）就公司召开 2024 年度股东大会（以下简称"本次股东大会"） 出具法律意见书。 一、本次股东大会召集人资格和召集、召开的程序 经核查，本次股东大会是由公司第二届董事会召集，公司已于 2025 年 ...

Core Viewpoint - The Chinese vaccine industry is facing unprecedented challenges in 2024, with significant declines in market value and vaccine issuance, leading to a search for recovery strategies amidst a harsh environment [1] Group 1: Market Dynamics - The total market value of 11 A-share vaccine companies is less than the peak value of Zhifei Biological three years ago [1] - The issuance of HPV vaccines has plummeted by over 60%, while flu and rabies vaccines are embroiled in price wars [1] - The strategy of "exchanging price for volume" has failed, leading to high inventory pressures and cash flow issues for companies [1] Group 2: Structural Challenges - The industry faces a dual challenge of oversupply in low-end markets and a lack of high-end products, with over 10 companies competing in the rabies and flu vaccine markets [2] - High-end vaccines like shingles and multi-valent vaccines are still dominated by foreign companies such as GSK [2] - Companies are caught in a dilemma of high R&D costs, long return cycles, and rapid market changes [2] Group 3: Strategies for Survival - Companies are increasing investment in multi-valent vaccines, with Watson Bio and Kangtai Bio leading the charge [3] - Zhifei Biological is building a product matrix to reduce dependency on single products, while Kangtai Bio is developing 13 pipeline products [3] - Collaborations for international market access, such as Kanghua Bio's partnership with HilleVax, are emerging as a survival strategy for smaller firms [3] Group 4: Future Outlook - The current dark period for the vaccine industry may serve as a starting point for value reassessment [4] - Companies that possess strong technology, diverse product portfolios, and global market access are likely to survive the supply-side cleansing [4] - The potential for Chinese vaccine companies to develop world-class products will determine the industry's future [4]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：301207 证券简称：华兰疫苗公告编号：2025-022 华兰生物疫苗股份有限公司 关于召开2024年度股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 华兰生物疫苗股份有限公司（以下简称"公司"）已于2025年3月29日在《证券时报》、《中国证券 报》、《上海证券报》及巨潮资讯网（www.cninfo.com.cn）披露了《关于召开2024年度股东大会的通 知》（公告编号：2025-020）。本次股东大会采取现场投票和网络投票相结合的表决方式召开，根据有 关规定，现将股东大会的相关事项再次提示如下： 一、召开会议的基本情况 1、股东大会届次：2024年度股东大会； 2、股东大会召集人：公司董事会； 3、会议召开的合法、合规性：本次股东大会会议的召开符合有关法律、行政法规、部门规章、规范性 文件和公司章程的规定。 4、会议召开方式：现场投票+网络投票 （1）现场投票：股东本人出席现场会议或者通过授权委托书（附件二）委托他人出席现场会议； （2）网络投票：本次股东大会通过深圳证券交 ...

Core Viewpoint - The price war in the influenza vaccine market has significantly impacted the financial performance of Jindike, leading to a substantial decline in revenue and profitability for the second consecutive year [1][5]. Financial Performance - In 2024, Jindike reported operating revenue of 80.8027 million yuan, a year-on-year decrease of 39.96%, resulting in a net loss of 93.5028 million yuan [2][6]. - The company has experienced a continuous decline in performance, with losses reported for three consecutive years from 2021 to 2023 [6]. - The price reduction of the four-valent influenza vaccine has contributed to the company's financial struggles, with the average price dropping from 128 yuan to 88 yuan, a decrease of 31.25% [6][7]. Product and Sales Performance - Jindike's only marketed product is the four-valent influenza virus split vaccine, which saw a 30% price reduction in 2024, leading to a significant compression of profit margins [3][8]. - The sales volume of the four-valent influenza vaccine was 1.1697 million doses in 2024, a year-on-year decrease of 15.32% [9]. - The company's gross margin for the four-valent influenza vaccine was 62.61% in 2024, down 15.2 percentage points from the previous year [8]. R&D and Future Plans - To reduce reliance on a single product, Jindike has increased its R&D investment, which accounted for 51.81% of its revenue in 2024, totaling approximately 41.8629 million yuan [12][13]. - The company is focusing on the development of a rabies vaccine, which has completed Phase III clinical trials and is currently undergoing product registration [4][15]. - Jindike is also expanding its product pipeline to include vaccines for chickenpox, shingles, and pneumococcal diseases, with ongoing clinical trials for its pediatric four-valent influenza vaccine [16].

Core Viewpoint - The domestic largest influenza vaccine manufacturer, Hualan Biological Engineering, has reported significant declines in revenue and net profit due to price wars and low vaccination rates, marking the lowest figures in five years [1] Group 1: Financial Performance - In 2024, Hualan Biological achieved an operating income of 1.128 billion yuan, a year-on-year decrease of 53.21% [1] - The net profit for the same year was 206 million yuan, down 76.10% year-on-year [1] - The gross profit margin for influenza vaccines was 81.84%, reflecting a decline of 6.45% compared to the previous year [2] - The net cash flow from operating activities was 468 million yuan, a decrease of 47.29% year-on-year, indicating weakened cash flow due to reduced sales collections [2] Group 2: Market Dynamics - The influenza vaccine market is experiencing intense price competition, with Hualan's main product prices reduced by approximately 30%, directly impacting revenue and gross margins [1][2] - The vaccination rate in China remains low at around 3%, significantly below global levels, with only about 60% of the total approved vaccine quantity actually administered [2] - The market demand for influenza vaccines has shown increased volatility, with a reported waste rate of approximately 40% in 2024, doubling from 20% in 2018 [2] Group 3: Production and Sales Trends - In 2024, the number of batches for the trivalent influenza vaccine increased from 6 to 11, a year-on-year growth of 83.33%, while the quadrivalent vaccine batches decreased from 88 to 67, a decline of 23.86% [3] - The sales volume of vaccines was 14.2419 million doses, down 26.58% year-on-year, and the production volume was 21.1131 million doses, down 16.74% year-on-year [3] - The HPV vaccine market has also shifted from a previous shortage to a more balanced supply-demand situation, with significant increases in production capacity [3][4] Group 4: Future Outlook - Despite current market pressures, Hualan Biological remains optimistic about the domestic influenza vaccine market, anticipating growth potential driven by government policies and increased public awareness of vaccination [4] - The company faces the challenge of navigating through the dual pressures of price wars and low vaccination rates to achieve market breakthroughs [4]

证券代码：301207 证券简称：华兰疫苗 公告编号：2025-021 华兰生物疫苗股份有限公司关于举办2024年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 华兰生物疫苗股份有限公司（以下简称"公司"）于2025年3月29日在巨潮资讯网（www.cninfo.com.cn） 披露了《公司2024年年度报告》。为便于广大投资者进一步了解公司2024年度的经营情况及未来发展规 划，公司将于2025年4月16日（周三）15:30-17:00通过深圳证券交易所"互动易"平台以网络方式举办 2024年度业绩说明会（以下简称"本次说明会"），现将有关事项公告如下： 一、本次说明会的安排 （一）召开时间：2025年4月16日15:30-17:00 登录新浪财经APP 搜索【信披】查看更多考评等级 华兰生物疫苗股份有限公司董事会 2025年4月9日 为充分尊重投资者，提升公司与投资者交流的效率和针对性，公司现就本次说明会提前向投资者公开征 集问题，广泛听取投资者的意见和建议。投资者可提前登录"互动易"平台，进入"业绩说明会提问预征 集"界面（htt ...

华兰生物疫苗股份有限公司 未来三年（2025-2027 年）股东分红回报规划 为进一步健全和完善华兰生物疫苗股份有限公司（以下简称"公司"）对利润 分配事项的决策程序和机制，积极回报投资者，引导投资者树立长期投资和理性 投资理念，根据中国证券监督管理委员会《上市公司监管指引第 3 号—上市公司 现金分红》和《公司章程》等相关文件规定，制订本《华兰生物疫苗股份有限公 司未来三年（2025-2027 年）股东分红回报规划》。 一、本规划制定原则 公司坚持实行持续、稳定的利润分配政策。制定本规划，在符合国家相关法 律法规及《公司章程》有关利润分配相关条款的前提下，既要重视对投资者稳定 的合理回报，同时还要充分考虑公司的实际经营情况和可持续发展。 公司董事会、监事会和股东大会对利润分配政策的决策和论证过程中应当充 分听取中小股东的意见和诉求，及时答复中小股东关心的问题。在充分尊重股东 利益的基础上，兼顾处理好公司短期利益及长远发展的关系。公司利润分配不得 超过累计可供分配利润的范围，不得损害公司持续经营能力。 二、制定本规划考虑的因素 公司制定本规划，着眼于公司的可持续发展，在综合分析公司盈利能力、股 东回报、社会资 ...